Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 18/20 | 0.85 |
| ▸ | JAK1 | P23458 | 2/20 | 0.57 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526017 | 0.92 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL26970322 | 0.90 | MAP4K1 (0.84) | MAP4K1JAK1JAK3 | |
| SCHEMBL29526800 | 0.90 | MAP4K1 (0.84) | MAP4K1JAK1JAK3 | |
| SCHEMBL26970262 | 0.84 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL29526134 | 0.84 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL29527066 | 0.83 | MAP4K1 (0.81) | MAP4K1JAK1JAK3 | |
| SCHEMBL26970329 | 0.83 | MAP4K1 (0.81) | MAP4K1JAK1JAK3 | |
| SCHEMBL26970242 | 0.82 | MAP4K1 (0.64) | MAP4K1 | |
| SCHEMBL29526277 | 0.82 | MAP4K1 (0.64) | MAP4K1 | |
| SCHEMBL29525815 | 0.81 | MAP4K1 (0.91) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240362-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2022098809-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | WO | claimed |
| US-20230416225-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4240362-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022098809-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416225-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | PDXK, PHKG1, PHKG2 | MAP4K1 59/4885JAK1 1576/4885JAK3 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.